Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 8
  1. Flutamide. Leuprolide is a luteinizing hormone-releasing hormone (LHRH) agonist used as androgen deprivation therapy in patients with advanced prostate cancer. Initiation of LHRH agonists causes an initial flare phenomenon of elevated testosterone and luteinizing hormone that manifests clinically as an increase in disease-related symptoms, such as bone pain, urinary obstruction, or cord compression. Coadministration of antiandrogens such as flutamide prior to initiating LHRH agonists blocks the effect of the initial hormonal elevation. As castrate levels of testosterone are predictably reached within the first several weeks of therapy, antiandrogens are only required for the first 21 to 28 days of LHRH treatment to prevent the flare phenomenon.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 2/25/08 • nvf